Thus, at a first approach, our patient with a stage IIA HR+/HER2+ tumor could have been reasonably treated with neoadjuvant paclitaxel plus anti-HER2 double blockade and posterior adjuvant trastuzumab or T-DM1 depending on pathologic response and endocrine therapy. This evidence concerns the gene ERBB2 and neoplasm.